Screener
Crinetics Pharmaceuticals CRNX Inventories
Inventories at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InventoryNet.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Cash and cash equivalents | $114,341 | $101,536 |
| Investment securities, amortized cost of $1,178,076 at March 31, 2026 and $924,317 at December 31, 2025 | 1,176,965 | 926,353 |
| Trade accounts receivable, net | 5,683 | 592 |
| Inventory | 3,064 | 2,022 |
| Prepaid expenses and other current assets | 22,361 | 17,839 |
| Total current assets | 1,322,414 | 1,048,342 |
| Property and equipment, net | 13,497 | 14,296 |
| Operating lease right-of-use assets | 39,790 | 40,492 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Crinetics Pharmaceuticals's inventories?
- Crinetics Pharmaceuticals (CRNX) reported inventories of $3.06M in Q1 2026.
- What does inventories mean?
- Total inventory including raw materials, work-in-progress, and finished goods, valued at the lower of cost or net realizable value.
Ask your AI about Crinetics Pharmaceuticals's inventories.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude